[HTML][HTML] Carcinoma of unknown primary site (CUP) with metastatic renal-cell carcinoma (mRCC) histologic and immunohistochemical characteristics (CUP-mRCC) …
A Overby, L Duval, M Ladekarl, BE Laursen… - Clinical genitourinary …, 2019 - Elsevier
Background Carcinoma of unknown primary site (CUP) is a heterogenous group of
metastatic cancer with no detectable primary tumor site. Diagnostic assessment occasionally …
metastatic cancer with no detectable primary tumor site. Diagnostic assessment occasionally …
[HTML][HTML] Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study
XQ Yan, MJ Ye, Q Zou, P Chen, ZS He, B Wu, DL He… - Annals of …, 2024 - Elsevier
Background Immune checkpoint inhibitors in combination with tyrosine kinase inhibitors are
standard treatments for advanced clear cell renal cell carcinoma (RCC). This phase III …
standard treatments for advanced clear cell renal cell carcinoma (RCC). This phase III …
[HTML][HTML] Real-world evidence data on metastatic renal-cell carcinoma treatment in Austria: the RELACS study
M Schmidinger, R Pichler, W Loidl… - Clinical Genitourinary …, 2019 - Elsevier
Background Treatment decisions in routine clinical practice are based on reports of clinical
trials, which represent highly selected populations. Limited studies reported real-world …
trials, which represent highly selected populations. Limited studies reported real-world …
[PDF][PDF] Anders Overby, Lone Duval, Morten Ladekarl
BE Laursen, F Donskov - researchgate.net
Diagnostic assessment occasionally presents carcinoma of unknown primary site (CUP)
with metastatic renalcell carcinoma (mRCC) histologic and immunohistochemical …
with metastatic renalcell carcinoma (mRCC) histologic and immunohistochemical …